U.S. markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.09
    +0.45 (+0.99%)
     
  • Gold

    1,842.00
    +0.90 (+0.05%)
     
  • Silver

    24.32
    +0.18 (+0.76%)
     
  • EUR/USD

    1.2127
    -0.0022 (-0.18%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • GBP/USD

    1.3438
    -0.0015 (-0.11%)
     
  • USD/JPY

    104.1400
    +0.2800 (+0.27%)
     
  • BTC-USD

    19,093.57
    +29.55 (+0.16%)
     
  • CMC Crypto 200

    365.19
    -14.05 (-3.71%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Recap: Quidel Q3 Earnings

Benzinga Insights
·1 min read

Shares of Quidel (NASDAQ:QDEL) fell 1.5% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 725.71% over the past year to $5.78, which beat the estimate of $4.75.

Revenue of $476,058,000 up by 276.35% year over year, which beat the estimate of $450,390,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Quidel hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Oct 29, 2020

View more earnings on QDEL

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/wcc/r/2625296/E75E2243C47118925001E5956E2A2D04

Technicals

52-week high: $306.72

52-week low: $55.42

Price action over last quarter: down 6.89%

Company Description

Quidel Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. It is separated into four product categories: Rapid immunoassays, Cardiac immunoassays, Specialized diagnostic solutions and Molecular diagnostic solutions. Rapid immunoassay and Cardiac immunoassay tests for use in physician offices, hospital laboratories and emergency departments, retail clinics, eye health settings, pharmacies and other urgent care sites, Specialized diagnostic solutions, including direct fluorescent assays and culture-based tests, and Molecular diagnostic tests across a number of hospitals, moderately complex physician offices, laboratories and other segments. The company generates a majority of its revenue from the rapid immunoassays.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.